This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors

NCT07327632 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: IBI3026

Sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center)